Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
Expanded Access of Cabozantinib in Medullary Thyroid Cancer
- Conditions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Exelixis
- Registration Number
- NCT01683110
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT01663272
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 659
- Registration Number
- NCT01658878
- Locations
- 🇺🇸
Local Institution - 0002, Ann Arbor, Michigan, United States
🇺🇸Local Institution - 0008, Los Angeles, California, United States
🇺🇸Local Institution - 0048, Washington, District of Columbia, United States
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 86
- Registration Number
- NCT01639508
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT01630590
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
- Conditions
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 1028
- Registration Number
- NCT01605227
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
- First Posted Date
- 2012-05-16
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 19
- Registration Number
- NCT01599793
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Cabozantinib in Advanced Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT01588821
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT01582295
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
XL-184+Abiraterone in Post-Chemo CRPC
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT01574937
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.